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Gleason score at the margin can predict biochemical recurrence after radical
prostatectomy, in addition to preoperative PSA and surgical margin status
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Background/aim: To evaluate the relation between biochemical recurrence (BCR) of prostate cancer and the extent of positive surgical
margins (PSMs), Gleason score (GS) of the tumor at the margins, and preoperative prostate-specific antigen (PSA) levels.
Materials and methods: A total of 94 patients who underwent radical prostatectomy were recruited for this study and received
postoperative follow-up care for 2 years. All specimens were evaluated for surgical margin status, PSM length, GS at positive margin, size
of tumor, multifocality, invasion of seminal vesicle, lymphovascular invasion, and perineural invasion. PSM was defined as a prostate
tumor.
Results: Out of 94 patients, 34 patients (36.2%) had PSMs and 46 patients (48.9%) had BCR. A statistically significant relation between
having a high risk of BCR of prostate cancer and having high preoperative PSA levels (P < 0.001), PSMs (P < 0.001), or a high GS at the
surgical margin (P = 0.024) was found.
Conclusion: High preoperative PSA levels, PSMs, and tumors with high GS at the margins have a poor prognostic impact, and
they correlate with a higher rate of BCR. Close follow-up of patients with PSMs with high GS and high levels of preoperative PSA is
recommended.
Key words: Prostate cancer, surgical margin, biochemical recurrence

1. Introduction
A positive surgical margin (PSM) in a radical prostatectomy
specimen means that the tumor has not completely been
excised and that the cancer has extended outside the
prostate into the resection margins (1–4). On pathologic
examination of prostate specimens, a PSM is the presence
of tumor cells at the inked margin. If there is a fibrin layer
between the tumor cells and the ink, it is considered as
negative (3). In addition, if the ink is on tumor cells in
which the glandular structure is not disrupted, it is again
considered as negative (3). Surgical margins are considered
as positive when tumor cells with disrupted glandular
structure are identified on the inked surface (3). However,
PSM may occur artificially when neoplastic glands are
exposed to disruption of the prostatic capsule during
surgery, tissue trauma during the intraoperative retraction
* Correspondence: seymaozkanli@gmail.com

of the prostate gland, or disruption of the capsule during
pathological processing of the specimen (4).
Disease recurrence in organ-confined prostate cancer
is reported to occur in up to 27% of the patients after
radical prostatectomy (RP) (5–7). The prognostic impact
of PSM on the outcomes after RP is controversial (7). The
association of biochemical recurrence (BCR) with PSM
has been studied and was found to be highly variable due
to the multiple causes underlying PSM (1–4).
Previous studies have found that margin status is not
an independent predictor of BCR when adjusted for other
factors, such as Gleason score (GS) and preoperative serum
prostate-specific antigen (PSA) levels (6,8). Nevertheless,
several studies have demonstrated that a higher rate
of BCR, local recurrence, and development of distant
metastasis are associated with PSM (9–11). Moreover,
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some reports have shown that PSM is an independent
predictor of BCR following RP (9,12,13). Although the
current TNM staging system does not reflect the impact
of PSM, recent reports have shown that patients with a
PSM but no extracapsular extension had PSA recurrence
rates similar to or worse than patients with extracapsular
extension with or without positive margins (14–16).
Recently, a PSM of greater than 3 mm was identified
as an independent predictor of BCR (17). Most of the data
evaluating these margin-based parameters originate from
large open prostatectomy series with intermediate to long
follow-up periods (18).
In the literature, there are many published studies that
evaluated the relationship between BCR and tumor GS.
However, there was only one study that looked into the
relationship among PSM, GS, and BCR. Song et al. (7)
showed that GS and BCR are 2 independent prognostic
factors for biochemical recurrence in patients with PSM.
In addition to the study by Song et al., our study is another
one that evaluates the GS at the PSM. We have investigated
the correlation of BCR with the length of PSM, GS at the
surgical margin, and preoperative PSA in patients who
underwent RP for the treatment of prostatic cancer.
2. Materials and methods
2.1. Patient population
We reviewed the data of patients who underwent
RP for the treatment of prostate cancer and received
postoperative follow-up care for more than 2 years at
our institution between September 2001 and March
2010. Clinical (age and PSA level) and pathological data
were collected prospectively into an institutional review
board-approved database. Follow-up data were gathered
from chart reviews so that only patients followed at our
institution were represented. Among these patients, those
with pathologic stage T2 and T3 were identified, while the
patients with node-positive disease and neoadjuvant or
adjuvant therapy were excluded from the study. As a result,
94 patients were included in our study group.
The patients underwent routine evaluation and PSA
testing every 3–6 months in the first 2 years and annually
thereafter in the postoperative period. BCR was defined as
a serum PSA level of ≥0.2 ng/mL after RP.
2.2. Pathologic evaluation
Using a standard protocol, we systematically sampled
and evaluated all RP specimens (19). The prostatic apex
was also evaluated in the same fashion in each protocol,
and the entire external surface of the prostate was inked.
The distal 5 to 8 mm (apex) was amputated and sectioned
parallel to the urethra. PSM was defined as prostate tumor
in contact with ink. The length of PSM was categorized
as either being <10 mm or ≥10 mm. In addition to the
surgical margin status, the PSM length, GS at the margin,
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largest diameter of the tumor, multifocality, presence of
seminal vesicle (SVI), lymphovascular invasions (LVIs),
and perineural invasions (PNIs) were also evaluated.
2.3. Statistical analysis
For statistical analysis of the data, SPSS 15.0 for Windows
was used. The chi-square test and Fisher’s exact chisquare test were used for the evaluation of quantitative
parameters. Logistic regression analysis was used for
multivariate analysis and for statistical significance,
and a P-value of less than 0.05 was considered to show
statistically significant results.
3. Results
We have included 94 patients that underwent RP between
2001 and 2010 at our institution. The age of the patients
ranged between 42 and 73 years old with a mean of 62.81
± 6.87. The demographics of the study are given in Table 1.
Table 1. Demographics and histological findings of patients.
n

%

<65

51

54.3

≥65

43

45.7

<4 ng/mL

4

4.3

4–10 ng/mL

44

46.8

>10 ng/mL

46

48.9

Positive

34

36.2

Negative

60

63.8

Length of tumor at the

<10 mm

18

52.9

margin (n = 34)

≥10 mm

16

47.1

<7

52

55.3

≥7

42

44.7

<25 mm

60

63.8

≥25 mm

34

36.2

Positive

21

22.3

Negative

73

77.7

Positive

30

31.9

Negative

64

68.1

Yes

46

48.9

No

48

51.1

Positive

64

68.1

Negative

30

31.9

Age

Preop. PSA (ng/mL)

Surgical margins

GS at the margin
Largest tumor diameter
SVI
LVI
BCR
PNI

PSA, prostate-specific antigen; GS, Gleason score; SVI,
seminal vesicle invasion; LVI, lymphovascular invasion; BCR,
biochemical recurrence; PNI, perineural invasion.
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We have analyzed the patients according to the
presence of BCR in the follow-up examinations. A
statistically significant relation was detected between BCR
and the preoperative PSA levels (P = 0.01). Patients with
a preoperative PSA level of >10 ng/mL had a statistically
significant higher BCR rate compared to those with
preoperative PSA levels of <10 ng/mL. In addition, a
statistically significant relation was found between higher
BCR rate (P = 0.01) and PSM; however, the relation
between BCR rate and the length of tumor at the PSM was
not statistically significant (P = 1). BCR rate and GS at the
surgical margin were found to be significantly related (P =
0.024). Patients with BCR had a significantly higher GS (GS
≥ 7) at the margin. Additionally, patients with BCR had a
significantly higher rate of SVI and LVI. The correlation
of BCR with the other clinical and histopathological
parameters is summarized in Table 2.
Table 3 summarizes the logistic regression analysis of
BCR. Parameters, from the most significant downwards,
were as follows: SVI (OR: 13.122), LVI (OR: 6.443),

preoperative PSA (OR: 4.229), and PSM length of >10 mm
(OR: 3.931). There was no relation between BCR and GS
of ≥7 at the PSM.
When patients were analyzed according to the surgical
margin status, it was seen that patients with PSMs had
higher preoperative PSA levels (>10 ng/mL) compared to
the patients with negative surgical margins. A statistically
significant relation was detected between PSM and GS at
the margin (P = 0.003); patients with a PSM had a higher
rate of having GS of ≥7 compared to negative surgical
margins. We found a significant relation between PSM and
SVI (P = 0.023), LVI (P = 0.001), and PNI (P = 0.007). In
addition to all these findings summarized in Table 4, no
significant relation was detected between PSM and age or
tumor size.
Table 5 summarizes the logistic regression analysis of
PSM with other parameters, which are listed from the most
significant downwards: LVI (OR: 3.761) and preoperative
PSA (OR: 3.251). There was no relation between PSM and
GS of ≥7 at the PSM, SVI, or PNI.

Table 2. Relation between biochemical recurrence of prostate cancer (BCR) and clinicopathologic factors.
BCR
Yes

Age

Preop. PSA

Surgical margins
Length of tumor at the margin
GS at the margin
Tumor size
SVI
LVI
PNI

No

n (%)

n (%)

<65

26 (56.5%)

25 (52.1%)

≥65

20 (43.5%)

23 (47.9%)

<4 ng/mL

1 (2.2%)

3 (6.3%)

4–10 ng/mL

12 (26.1%)

32 (66.7%)

>10 ng/mL

33 (71.7%)

13 (27.1%)

Positive

26 (56.5%)

8 (16.7%)

Negative

20 (43.5%)

40 (83.3%)

<10 mm

14 (53.8%)

4 (50.0%)

≥10 mm

12 (46.2%)

4 (50.0%)

<7

20 (43.5%)

32 (66.7%)

≥7

26 (56.5%)

16 (33.3%)

<25 mm

27 (58.7%)

33 (68.8%)

≥25 mm

19 (41.3%)

15 (31.2%)

Positive

20 (43.5%)

1 (2.1%)

Negative

26 (56.5%)

47 (97.9%)

Positive

26 (56.5%)

4 (8.3%)

Negative

20 (43.5%)

44 (91.7%)

Positive

34 (73.9%)

30 (62.5%)

Negative

12 (26.1%)

18 (37.5%)

P

0.666

0.001**

0.001**
1
0.024*
0.391
0.001**
0.001**
0.235

PSA, prostate-specific antigen; GS, Gleason score; SVI, seminal vesicle invasion; LVI, lymphovascular invasion; BCR,
biochemical recurrence; PNI, perineural invasion. Chi-square test: * P < 0.05, ** P < 0.001.
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Table 3. Logistic regression analysis of biochemical recurrence (BCR) of prostate cancer and clinicopathologic factors.
B

SE

P

OR

95% CI

Preop. PSA (>10 ng/mL)

1.442

0.587

0.014*

4.229

1.338–13.363

Tumor length at margin

1.369

0.626

0.029*

3.931

1.152–13.416

GS (≥7) at the margin

–0.762

0.670

0.256

0.467

0.126–1.736

SVI (positive)

2.574

1.152

0.025*

13.122

1.372–125.532

LVI (positive)

1.863

0.780

0.017*

6.443

1.396–29.746

PSA, prostate-specific antigen; GS, Gleason score; SVI, seminal vesicle invasion; LVI, lymphovascular invasion; BCR,
Biochemical Recurrence; B, beta coefficient; SE, standard error; OR, odds ratio; CI, correlation index.

Table 4. Relation between surgical margin status and clinicopathologic features.
Surgical margin

Age

Preop. PSA

GS at the margin
Tumor size
SVI
LVI
PNI

Positive

Negative

n (%)

n (%)

<65

17 (50.0%)

34 (56.7%)

>65

17 (50.0%)

26 (43.3%)

<4 ng/mL

1 (2.9%)

3 (5.0%)

4–10 ng/mL

9 (26.5%)

35 (58.3%)

>10 ng/mL

24 (70.6%)

22 (36.7%)

<7

12 (35.3%)

40 (66.7%)

≥7

22 (64.7%)

20 (33.3%)

<25 mm

19 (55.9%)

41 (68.3%)

≥25 mm

15 (44.1%)

19 (31.7%)

Positive

12 (35.3%)

9 (15.0%)

Negative

22 (64.7%)

51 (85.0%)

Positive

19 (55.9%)

11 (18.3%)

Negative

15 (44.1%)

49 (81.7%)

Positive

29 (85.3%)

35 (58.3%)

Negative

5 (14.7%)

25 (41.7%)

P

0.533

0.007**

0.003**
0.227
0.023*
0.001**
0.007**

PSA, prostate-specific antigen; GS, Gleason score; SVI, seminal vesicle invasion; LVI, lymphovascular invasion;
BCR, biochemical recurrence; PNI, perineural invasion. Chi-square test: * P < 0.05, ** P < 0.001.

Finally, patients with PSMs were analyzed and a
statistically significant relation was detected between
BCR and high preoperative PSA (P = 0.029). Patients with
preoperative PSA of >10 ng/mL had a higher rate of BCR.
Additionally, in these patients, a significant relation was
detected between BCR and GS at the margin (P = 0.024).
Patients with BCR had significantly higher GS results (GS
≥ 7) at the margin. BCR also had a significant relation with
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SVI (P = 0.017) and LVI (P = 0.01). These findings are
summarized in Table 6.
Table 7 shows the logistic regression analysis of
PSM with other parameters, which are listed from the
most significant to less significant: LVI (OR: 6.074) and
preoperative PSA (OR: 4.721). There was no relationship
between PSM and GS of ≥7 at the PSM, SVI, or PNI.
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Table 5. Logistic regression analysis of positive surgical margin (PSM) and clinicopathologic factors.
B

SE

P

OR

95% CI

Preop. PSA (>10 ng/mL)

1.179

0.525

0.025*

3.251

1.162–9.093

GS (≥7) at the margin

0.439

0.544

0.419

1.552

0.534–4.506

SVI (positive)

–0.512

0.723

0.478

0.599

0.145–2.471

LVI (positive)

1.325

0.626

0.034*

3.761

1.104–12.820

PNI (positive)

0.967

0.634

0.127

2.630

0.759–9.107

PSA, prostate-specific antigen; GS, Gleason score; SVI, seminal vesicle invasion; LVI, lymphovascular
invasion; PNI, perineural invasion; B, beta coefficient; SE, standard error; OR, odds ratio; CI, correlation
index.

Table 6. Relation between biochemical recurrence of prostate cancer (BCR) and clinicopathologic
factors in patients with positive surgical margin (PSM).
BCR

Age

Preop. PSA

GS at the margin

Tumor size

SVI

LVI

PNI

Present

Absent

n (%)

n (%)

<65

13 (50.0%)

4 (50.0%)

>65

13 (50.0%)

4 (50.0%)

<4 ng/mL

0 (0.0%)

1 (12.5%)

4–10 ng/mL

5 (19.2%)

4 (50.0%)

>10 ng/mL

21 (80.8%)

3 (37.5%)

<7

8 (30.8%)

4 (50.0%)

≥7

18 (69.2%)

4 (50.0%)

<25 mm

14 (53.8%)

5 (62.5%)

≥25 mm

12 (46.2%)

3 (37.5%)

Positive

12 (46.2%)

0 (0.0%)

Negative

14 (53.8%)

8 (100.0%)

Positive

19 (73.1%)

0 (0.0%)

Negative

7 (26.9%)

8 (100.0%)

Positive

22 (84.6%)

7 (87.5%)

Negative

4 (15.4%)

1 (12.5%)

P

1

0.029*

0.320

1

0.017*

0.001**

1

PSA, prostate-specific antigen; GS, Gleason score; SVI, seminal vesicle invasion; LVI, lymphovascular
invasion; BCR, biochemical recurrence; PNI, perineural invasion. Chi-square test and Fisher’s exact
test: * P < 0.05, ** P < 0.01
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Table 7. Logistic regression analysis of prostate-specific antigen (PSA) recurrence and other parameters in
positive surgical margin (PSM) cases.
B

SE

P

OR

95% CI

Preop. PSA (>10 ng/mL)

1.552

0.535

0.004**

4.721

1.654–13.481

GS (≥7) at the margin

–0.389

0.594

0.512

0.677

0.212–2.169

SVI (positive)

1.674

0.882

0.058

5.333

0.947–30.027

LVI (positive)

1.804

0.693

0.009**

6.074

1.563–23.606

PSA, prostate-specific antigen; GS, Gleason score; SVI, seminal vesicle invasion; LVI, lymphovascular invasion;
PNI, perineural invasion; B, beta coefficient; SE, standard error; OR, odds ratio; CI, correlation index.

4. Discussion
While many studies have reported that patients with
positive margin prostate cancer are more likely to progress
biochemically, locally, and systemically (20–24), the
prognostic significance of a PSM in the case of organconfined cancer remains debatable (7).
Traditionally, the extent of a PSM in RP specimens was
categorized as focal or extensive (3,4,10,18). The major
issue with this method is the lack of a standard to define
how much of a tumor at the margin should be considered
a focal or extensive positivity. This makes it difficult
to compare the results among studies. As a result, the
International Society of Urological Pathology has recently
recommended reporting the length of PSMs as the extent
of a positive margin (25). Only a few studies have been
published on this subject (4,10,18,26,27). Shikanov et
al. found that the length of a PSM was an independent
prognostic factor for BCR, both as a continuous variable
and as a categorical variable (≤1 mm, 1–3 mm, or >3 mm)
(18). Ochiai et al. found that the prognosis of patients with
a length of tumor at the surgical margin of ≤3.0 mm and
those with a length of PSM of >3.0 mm were statistically
different (P < 0.01) (17). Other groups also made similar
observations (10,27) In contrast, Emerson et al. and Marks
et al. found that the length of PSM was not an independent
prognostic factor (26,28).
While evaluating the tumor length at the surgical
margin, we subgrouped the patients as having PSMs of less
than 10 mm and having PSMs of greater than or equal to 10
mm in our study. We confirmed that BCR is much higher
in cases with PSMs (36.2%). However, the tumor length
at the surgical margin was independent from BCR. It is
clear that the number of cases in our study is not enough
to reach a statistically significant conclusion.
Shikanov et al. prospectively studied 1398 patients.
According to them, in patients with a PSM, the margin
length was associated with BCR. They found total PSM
length to be independently associated with BCR. Longer
positive margins are associated with higher risk of BCR.
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This emphasizes the importance of minimizing not
only the incidence but also the extent of PSM surgically.
Interestingly, in our study, the risk of BCR did not differ
between patients with a negative surgical margin and
those with a PSM of less than 1 mm. This finding suggests
that patients with a small positive margin have a falsepositive margin or that, given our relatively short followup, persistent microscopic disease following surgery has
yet to be translated into BCR (18).
Stephenson et al. analyzed follow-up data from 7160
patients treated with RP. They found that an increased risk
of biochemical recurrence was associated with multiple
versus solitary PSMs (adjusted HR: 1.4, P = 0.002) and
extensive versus focal PSMs (adjusted HR: 1.3, P = 0.004)
in multivariable analysis. Consequently, they reported that
the number and extent of PSMs significantly influence the
risk of biochemical recurrence after RP (4).
In the studies done to date, specimen GS has been
taken into consideration. However, as seen in a few other
studies, we assessed the GS at the surgical margin in order
to ascertain whether GS at the surgical margin has any
implication on the recurrence (7).
Song et al. evaluated the surgical margin GS, similar
to our study. On multivariate analysis, surgical GS was
independently prognostic of BCR. Song et al. found that
the surgical GS (P = 0.021) was the independent predictor
of BCR (7).
In our study, we also found that BCR is higher in PSM
cases with a GS of ≥7 at the margin. Our findings support
that having a tumor with GS of ≥7 at the margin increases
the PSA recurrence by at least 2.6 times.
In conclusion, certain factors can predict biochemical
recurrence after RP, including preoperative PSA levels,
surgical margin positivity, and GS of ≥7 at the PSM, in
patients with localized prostate cancer. There was no
relation between the length of the PSM and BCR when
cut-off was taken as 10 mm for the length. With the use of
several different cut-offs for the length of invasion, more
detailed analysis can be performed in a larger series.
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